The Algorithm of CSF Examination according to the Reccomendation of the Committee of CSF and Neuroimmunology of the Czech Neurological Society

Czech version

Authors: O. Sobek1ihash2 ^{,2 3}; M. Koudelková ¹; P. Štourač ⁴; J. Mareš ⁵
Authors‘ workplace: Laboratoř pro likvorologii a neuroimunologii (Akreditovaná laboratoř ČIA dle ČSN EN ISO 1 189, Expertní pracoviště SEKK pro ČR a SR) ¹; Neurologická klinika 3. LF UK a FN Královské Vinohrady, Praha ²; Neurologické odd. ÚVN v Praze ³; Neurologická klinika LF MU a FN Brno ⁴; Neurologická klinika LF UP a FN Olomouc ⁵
Published in: Cesk Slov Neurol N 2012; 75/108(2): 159-163
Category: Review Article

Overview

An overview of available assays of cerebrospinal fluid is presented, including those used in routine laboratory practice as well as specialized laboratory parameters. The portfolio of techniques is divided into two subgroups as per the Neuroimmunology and CSF Section of the Czech Neurological Society guidelines. These recommendations are based primarily on the guidelines issued by EFNS. The basic panel is intended for the type I CSF laboratories, the complete specialized assessment should be provided by type II super-consultation laboratories. Brief indication criteria and pre-analytical requirements for the individual methods are also presented.

Key words:
cerebrospinal fluid – cytology – proteinogram – immunoglobulins – isoelectric focusing – antibodies – cytokines – PCR

Sources

1. Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S.et al. Guidelines on routine cerebrospinal fluid analysis. Report from EFNS task force. Eur J Neurol 2006; 13(9): 913–922.

2. Deisenhammer F, Egg R, Giovannoni G, Hemmer B, Petzold A, Sellebjerg F et al. EFNS guidelines on disease-specific CSF investigations. Eur J Neurol 2009; 16(6): 760–770.

3. Mygland A, Ljostada U, Fingerled V, Rupprechte T, Schmutzhardf E, Steiner I. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 2010; 17(1): 8–16.

4. Sobek O, Adam P, Svatonova J. Letter to the Editor – Comments on published article by F. Deisenhammer et al. Eur J Neurol 2007; 14(6): e14.

5. Reiber H, Thompson EJ, Grimsley G, Bernardi G, Adam P, Monteiro de Almeida S.et al. Quality assurance for cerebrospinal fluid analysis: international consensus by an internet-based group discussion. Clin Chem Lab Med 2003; 41(3): 331–337.

6. Adam P, Taborsky L, Sobek O, Hildebrand T, Kelbich P, Průcha M, Hyanek J. Cerebrospinal Fluid. Adv Clin Chem 2001; 36: 1–62.

7. Felgenhauer K. Laboratory diagnosis of neurological diseases. In: Thomas L (ed). Clinical Laboratory Diagnostics.

A.Monograph. Frankfurt/Main: TH-Books 1998: 1317–1327.

8. Lamers KJ, Wevers RA . Cerebrospinal Fluid Diagnostics. Biochemical and Clinical Aspects. Klin Biochem Metab 1995; 24(2): 63–75.

9. Adam P, Taborsky L, Prucha M, Sobek O, Kratochvila J, Zeman D. Cerebrospinal Fluid Cytology. A.Monograph. Praha: Medica News Publishers 2000.

10. Zeman D, Adam P, Kalistova H, Sobek O, Anděl J, Anděl M. Cerebrospinal fluid cytological findings in multiple sclerosis. A.comparison between patient subgroups. Acta Cytol 2001; 45(1): 51–59.

11. Adam P, Taborsky L, Sobek O, Kelbich P, Průcha M. Proteinologie mozkomišniho moku. Praha: Medica News Publishers 2002.

12. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a concensus statement. Arch Neurol 2005; 62(6): 865–870.

13. Hořejši V, Bartůňkova J. Zaklady imunologie. Praha: Triton 2005.

14. Sobek O, Adam P. Letter to the editors: On S. Seyfert, V. Kunzmann, N. Schwertfeger, H. C. Koch, A. Faulstich: Determinants of lumbar CSF protein concentration. J Neurol 2003; 250(3): 371–372.

15. Krejsek J, Kopecky O. Klinicka imunologie. Hradec Kralove: Nucleus 2004.

16. Reiber H. The hyperbolic function: a mathematical solution of the protein flux/CSF flow model for blood-CSF barrier function. J Neurol Sci 1994; 126: 243–245.

17. Kelbich P, Koudelkova M, Machova H, Tomaškovič M, Vachata P, Kotalikova P et al. Vyznam urgentniho vyšetřeni CSF pro včasnou diagnostiku neuroinfekci. Klin Mikrobiol Inf Lek 2007; 13(1): 9–20.

18. Maier B, Laurer HL, Rose S, Buurman WA, Marzi I. Physiological Levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: A.normative Study. J Neurotrauma 2005; 22(7): 822–835.

19. Zeman D, Adam P, Kalistova H, Sobek O, Kelbich P, Andel J et al. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients. Acta Neurol Scand 2000; 101(2): 89–94.

20. Kleine TO, Damm T, Althaus H. Quantification of beta-trace protein and detection of transferrin isoforms in mixtures of cerebrospinal fluid and blood serum as models of rhinorrhea and otorrhea diagnosis. J Anal Chem 2000; 366(4): 382–386.

21. Bednarova J, Stourac P, Adam P. The diagnostical relevance of immunological variables in

neuroborreliosis and multiple sclerosis. Acta Neurol Scand 2005; 112(2): 97–102.

22. Zeman D, Vaničkova Z, Benakova H, Havrdova E. Volne lehke řetězce typu kappa v likvoru a seru. Klin Biochem Metab 2002; 10(2): 98–102.

23. Adam P, Sobek O, Taborsky L, Hildebrand T, Tutterova O, Zacek P. CSF and serum orosomucoid (alpha-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients. Clin Chim Acta 2003; 334(1–2): 107–110.

24. Stoeck K, Bodemer M, Zerr I. Pro- and anti-inflammatory cytokines in the CSF of patients with

Creutzfeld-Jocob disease. J Neuroimmunol 2006; 172(1–2): 175–181.

25. Aksamit AJ jr, Preissner CM, Homburger HA . Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt–Jakob disease. Neurology 2001; 57(4): 728–730.

26. Schoonenboom NS , Pijnenburg YA , Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ et al. Amyloid beta(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004; 62(9): 1580–1584.

27. Štourač P. Antineuronalni autoprotilatky vůči antigenům centralniho nervoveho systemu detekovane metodou Western blot a imunofluorescenci u pacientů s myasthenia gravis a L ambertovym-Eatonovym myastenickym syndromem. Klin Biochem Metab 1998; 6(4): 207–209.

28. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis and therapy. Lancet Neurol 2004; 1(5): 294–305.

29. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 2008; 5: 22.

30. Pruss H, Dalmau J, Harms L, Holtje M, Ahnert-Hilger G, Borowski K.et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010; 75(19):

1735–1739.

31. Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome: mini-review. J Neuroimmunol 2010; 223(1–2): 5–12.

32. Štourač P, Bednařova J. Intratekalni, antivirova a oligoklonalni IgG synteza u sclerosis multiplex a jeji vyznam v diferencialni diagnostice neurologickych onemocněni. Klin Biochem Metab 2000; 8(29): 204–208.

33. Aurelius E, Johansson B, Skoldenberg B, Staland A, Forsgren M. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 1991; 337(8735): 189–192.

34. Roine I, Saukkoriipi A, Leinonen M, Peltola H. Microbial genome count in cerebrospinal fluid compared with clinical characteristics in pneumococcal and Haemophilus influenzae type b meningitis in children. Diagn Microbiol Infect Dis 2009; 63(1): 16–23.

35. Tavakoli NP , Wang H, Nattanmai S, Dupuis M, Fusco H, Hull R. Detection and typing of enteroviruses from CSF specimens from patients diagnosed with meningitis/encephalitis. J Clin Virol 2008; 43(2): 207–11.

36. Doležil D, Štourač P, Hromada J. Paraneoplasticke syndromy postihujici centralni a periferni nervovy system. Trendy v medicině 2000; 2: 57–61.

37. Sindic CJ, Laterre E. Oligoclonal free kappa and lambda bands in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. An immunoaffinity-mediated capillary blot study. J Neuroimmunol 1991, 33(1): 63–72.

38. Sindic CJ, Monteyne P, Laterre EC . Occurrence of oligoclonal IgM bands in the cerebrospinal fluid of neurological patients: an immunoaffinity-mediated capillary blot study. J Neurol Sci 1994, 124(2): 215–219.

39. Rijcken CA, Thompson EJ, Teelken AW. An improved, ultrasensitive method for the detection of IgM oligoclonal bands in cerebrospinal fluid. J Immunol Methods 1997, 203(2): 167–169.

40. Villar LM, Gonzalez-Porque P, Masjuan J, Alvarez-Cermeno JC, Bootello A, Keir G. A.sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Methods 2001, 258(1–2): 151–155.

41. Villar LM, Masjuan J, Gonzalez-Porque P, Plaza J, Sadaba MC, Roldan E et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003, 53(2): 222–226.

42. Cruickshank A, Auld P, Beetham R, Burrows G, Egner W, Holbrook I.et al. Revised national guidelines for analysis of cerebrospinal fluid for bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem 2008, 45(3): 238–244.

43. Kleine TO , Zwerenz P, Zofel P, Shiratori K. New and old diagnostic markers of meningitis in cerebrospinal fluid (CSF). Brain Res Bull 2003, 61(3): 287–297.

44. Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside, Pharmacol Ther 2005, 106(2): 163–177.

45. Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 2010, 16(2): 208–217.

46. Pinto VL , Rebelo MC, Gomes RN , deAssis EF, Castro-Faria-Neto HC , Bola MN. IL -6 and IL -8 in cerebrospinal fluid from patients with aseptic meningitis and bacterial meningitis: their potential role as a marker for differential diagnosis. Braz J Infect Dis 2011, 15(2): 156–158.

47. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 2011; 18(1): 19.

48. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10(1): 63–74.

49. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77(2): 179–189.

50. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9(8): 776–785.